Prostate Cancer News
In a study, just 12.1% of cases with focal positive surgical margins (PSM) experienced biochemical recurrence compared with 54.1% of those with extensive PSM.
New data from a phase 2 randomized trial suggest that stereotactic ablative radiotherapy to sites of metastases may prolong overall and progression-free survival.
Men treated with 5-alpha reductase inhibitors were diagnosed with prostate cancer 2 years later than men not using these drugs.
New studies find no increase in biochemical recurrence risk following radical prostatectomy or radiation therapy associated with testosterone replacement therapy.
The Food and Drug Administration (FDA) has accepted for Priority Review the New Drug Application (NDA) for darolutamide (Bayer and Orion), an investigational treatment for non-metastatic castration-resistant prostate cancer (nmCRPC).
Two-year and three-year biochemical progression-free survival rate of 100 percent for low-risk disease
Focal laser ablation (FLA) of low- to intermediate-risk prostate cancer is associated with low morbidity and good oncologic outcomes.
New study finds that Vietnam War exposure to the defoliant Agent Orange is associated with a reduced death risk among men receiving androgen deprivation therapy for advanced prostate cancer.
Biparametric MRI detects prostate tumors with an accuracy similar to that of multiparametric MRI without the cost and risks associated with intravenous gadolinium contrast.
CD133 has often been used as a marker of cancer stem cells.
Among men with nonmetastatic castration-resistant prostate cancer, those who were treated with darolutamide had a 59% decreased risk of metastasis compared with placebo recipients.
After an additional 1 year of follow-up, apalutamide plus ADT continued to show a significant decrease in the risk of progression to metastasis or death.
The study is the first to show that treatment with abiraterone acetate/enzalutamide is associated with better survival in African American patients with mCRPC compared with Caucasians.
By targeting prostate-specific membrane antigen, a molecule radiolabeled with lutetium-177 is expected to deliver high doses of beta radiation to distant metastases.
The Decipher genomic classifier predicted metastases and prostate cancer-specific mortality following radical prostatectomy with greater precision in African-American men.
Patients with metastatic CRPC and bone metastases treated with abiraterone plus prednisone/prednisolone had a higher risk of bone fractures when receiving concomitant radium-223.
From 2010 to 2015, active surveillance/watchful waiting increased from 14.5% to 42.1%, according to a new study.
A high percentage of men with prostate cancer have 1 or more potentially pathogenic germline variants, but would not be eligible for mutation testing under current NCCN guidelines.
Biomarkers of PD-1/PD-L1 checkpoint inhibitor response in prostate cancer could help stratify patients by response.
Compared with men receiving androgen deprivation therapy for prostate cancer, healthy men had a 98% decreased risk of overactive bladder, study finds.